FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010052322> ?p ?o ?g. }

• W2010052322 endingPage "293" @default.
• W2010052322 startingPage "287" @default.
• W2010052322 abstract "The efficacy of chemotherapy for advanced gastric cancer with palliative intent compared with supportive care alone is now widely accepted. However, the best choice of chemotherapy regimen for patients with advanced gastric cancer is still a matter of controversy and requires further investigation. This study is performed to evaluate the efficacy and safety of the FOLFOXIRI regimen (oxaliplatin 85 mg/m2 as a 2-h intravenous infusion, irinotecan 165 mg/m2 as a 90-min infusion, leucovorin 200 mg/m2 as a 2-h infusion, 5-fluorouracil 3200 mg/m2 as a 48-h continuous infusion on day 1, every 2 weeks) as first-line treatment for advanced gastric cancer. Forty-seven (95.9%) of the 49 patients were assessable for response. Two cases of complete response and 29 cases of partial response were confirmed, giving an overall response rate of 63.3% [95% confidence interval (CI): 49.8–76.8%]. The median time to progression and overall survival for all patients were 7.3 months (95% CI: 6.0–8.6 months) and 11.9 months (95% CI: 9.4–14.4 months), respectively. The estimate of overall survival at 12 months was 42.9% (95% CI: 29.0–56.7%). Most patients experienced neutropenia during their course of therapy with 49% of patients (n=23) for grade 3/4 neutropenia. Grade 3 nausea/vomiting, stomatitis, and diarrhea were observed in 20 (42.6%), two (4.3%), and five (10.6%) patients, respectively. Yet, no grade 4 nonhematologic toxicity was observed. The FOLFOXIRI combination is a tolerated treatment modality with promising activity in previously untreated advanced gastric cancer patients." @default.
• W2010052322 created "2016-06-24" @default.
• W2010052322 creator A5011297387 @default.
• W2010052322 creator A5012821642 @default.
• W2010052322 creator A5014979883 @default.
• W2010052322 creator A5015225458 @default.
• W2010052322 creator A5027311139 @default.
• W2010052322 creator A5033145761 @default.
• W2010052322 creator A5040575560 @default.
• W2010052322 creator A5045398823 @default.
• W2010052322 creator A5087324266 @default.
• W2010052322 date "2009-04-01" @default.
• W2010052322 modified "2023-09-22" @default.
• W2010052322 title "Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer" @default.
• W2010052322 cites W1837926236 @default.
• W2010052322 cites W1965734230 @default.
• W2010052322 cites W1976651872 @default.
• W2010052322 cites W1992408996 @default.
• W2010052322 cites W2000435707 @default.
• W2010052322 cites W2016687759 @default.
• W2010052322 cites W2018925207 @default.
• W2010052322 cites W2029409133 @default.
• W2010052322 cites W2046076775 @default.
• W2010052322 cites W2051318720 @default.
• W2010052322 cites W2052457410 @default.
• W2010052322 cites W2060704373 @default.
• W2010052322 cites W2066546242 @default.
• W2010052322 cites W2087723344 @default.
• W2010052322 cites W2096139576 @default.
• W2010052322 cites W2108661938 @default.
• W2010052322 cites W2111837783 @default.
• W2010052322 cites W2113805173 @default.
• W2010052322 cites W2122866527 @default.
• W2010052322 cites W2123495698 @default.
• W2010052322 cites W2127191258 @default.
• W2010052322 cites W2128328462 @default.
• W2010052322 cites W2128775037 @default.
• W2010052322 cites W2130522735 @default.
• W2010052322 cites W2144466956 @default.
• W2010052322 cites W2145139896 @default.
• W2010052322 cites W2145390243 @default.
• W2010052322 cites W2146798192 @default.
• W2010052322 cites W2162517914 @default.
• W2010052322 cites W2167571044 @default.
• W2010052322 cites W2168645047 @default.
• W2010052322 cites W2279052620 @default.
• W2010052322 cites W4293241248 @default.
• W2010052322 cites W186567915 @default.
• W2010052322 doi "https://doi.org/10.1097/cad.0b013e3283273509" @default.
• W2010052322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19177020" @default.
• W2010052322 hasPublicationYear "2009" @default.
• W2010052322 type Work @default.
• W2010052322 sameAs 2010052322 @default.
• W2010052322 citedByCount "21" @default.
• W2010052322 countsByYear W20100523222012 @default.
• W2010052322 countsByYear W20100523222013 @default.
• W2010052322 countsByYear W20100523222014 @default.
• W2010052322 countsByYear W20100523222016 @default.
• W2010052322 countsByYear W20100523222017 @default.
• W2010052322 countsByYear W20100523222018 @default.
• W2010052322 countsByYear W20100523222019 @default.
• W2010052322 countsByYear W20100523222020 @default.
• W2010052322 countsByYear W20100523222022 @default.
• W2010052322 countsByYear W20100523222023 @default.
• W2010052322 crossrefType "journal-article" @default.
• W2010052322 hasAuthorship W2010052322A5011297387 @default.
• W2010052322 hasAuthorship W2010052322A5012821642 @default.
• W2010052322 hasAuthorship W2010052322A5014979883 @default.
• W2010052322 hasAuthorship W2010052322A5015225458 @default.
• W2010052322 hasAuthorship W2010052322A5027311139 @default.
• W2010052322 hasAuthorship W2010052322A5033145761 @default.
• W2010052322 hasAuthorship W2010052322A5040575560 @default.
• W2010052322 hasAuthorship W2010052322A5045398823 @default.
• W2010052322 hasAuthorship W2010052322A5087324266 @default.
• W2010052322 hasConcept C121608353 @default.
• W2010052322 hasConcept C126322002 @default.
• W2010052322 hasConcept C141071460 @default.
• W2010052322 hasConcept C2776694085 @default.
• W2010052322 hasConcept C2777063308 @default.
• W2010052322 hasConcept C2778336483 @default.
• W2010052322 hasConcept C2778496288 @default.
• W2010052322 hasConcept C2778850193 @default.
• W2010052322 hasConcept C2780259306 @default.
• W2010052322 hasConcept C2780456651 @default.
• W2010052322 hasConcept C2780580376 @default.
• W2010052322 hasConcept C2780852908 @default.
• W2010052322 hasConcept C2780962732 @default.
• W2010052322 hasConcept C2781413609 @default.
• W2010052322 hasConcept C31760486 @default.
• W2010052322 hasConcept C526805850 @default.
• W2010052322 hasConcept C71924100 @default.
• W2010052322 hasConcept C90924648 @default.
• W2010052322 hasConceptScore W2010052322C121608353 @default.
• W2010052322 hasConceptScore W2010052322C126322002 @default.
• W2010052322 hasConceptScore W2010052322C141071460 @default.
• W2010052322 hasConceptScore W2010052322C2776694085 @default.
• W2010052322 hasConceptScore W2010052322C2777063308 @default.
• W2010052322 hasConceptScore W2010052322C2778336483 @default.

• next